Superior diagnostic efficacy and cost advantage of FibroTouch over CHI3L1 for liver fibrosis in Chinese patients with chronic liver disease
Zhongbao Zuo, Chunli Yang, Lanlan Hu, Xiafen Ye, Yazhen Zhang, Lili Huang, Miaochan Wang, Huaizhong Cui · 2026
Read Superior diagnostic efficacy and cost advantage of FibroTouch over CHI3L1 for liver fibrosis in Chinese patients with chronic liver disease by Zhongbao Zuo, Chunli Yang, Lanlan Hu, Xiafen Ye, Yazhen Zhang, Lili Huang, Miaochan Wang, Huaizhong Cui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357883.txt.
Description
Zhongbao Zuo and seven colleagues published this research article in PLOS ONE in 2026. It compares two ways of assessing liver fibrosis, scarring of the liver, in patients in China who live with chronic liver disease: FibroTouch, an ultrasound-based device, and CHI3L1, a blood marker. The title claims FibroTouch diagnoses better and costs less.
Staging fibrosis decides treatment urgency, yet biopsy, the old standard, is invasive and costly. A device that is both more accurate and cheaper than a blood test would simplify clinic work greatly. Liver specialists and hospital purchasers in China are the readers weighing this head-to-head claim.
Catalog record
| CREATOR | Zhongbao Zuo, Chunli Yang, Lanlan Hu, Xiafen Ye, Yazhen Zhang, Lili Huang, Miaochan Wang, Huaizhong Cui |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30420 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |